Review: Coronavirus disease (COVID-19) in patients with hematologic malignancy
DOI:
https://doi.org/10.58931/cht.2023.2231Abstract
The Coronavirus disease that emerged globally in 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in December 2019, with rapid worldwide spread leading to a pandemic soon after. Three years later, although the virus now holds a diminished role in the public agenda, COVID-19 remains a real and present danger for patients with hematologic malignancy (HM). This paper provides an overview of the risks of COVID-19 in patients with HM, the effectiveness of vaccination, and management strategies in these vulnerable patients.
References
Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020 Dec 17;136(25):2881-92. DOI: https://doi.org/10.1182/blood.2020008824
He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, Wu D, Liang B, Lu X, Ma Y, Li L. COVID-19 in persons with haematological cancers. Leukemia. 2020 Jun;34(6):1637-45. DOI: https://doi.org/10.1038/s41375-020-0836-7
Candoni A, Pizzano U, Fabris M, Curcio F, Fanin R. Seroconversion and kinetic of anti SARS- COV-2 antibodies in 25 patients with hematological malignancies who recovered from SARS-COV-2 infection. Hematological Oncology. 2021 Aug;39(3):428. DOI: https://doi.org/10.1002/hon.2872
Cattaneo C, Cancelli V, Imberti L, Dobbs K, Sottini A, Pagani C, Belotti A, Re A, Anastasia A, Quaresima V, Tucci A. Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. Blood Cancer Journal. 2021 Sep 14;11(9):151. DOI: https://doi.org/10.1038/s41408-021-00546-9
Passamonti F, Romano A, Salvini M, Merli F, Porta MG, Bruna R, Coviello E, Romano I, Cairoli R, Lemoli R, Farina F. COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. British Journal of Haematology. 2021 Nov;195(3):371-7. DOI: https://doi.org/10.1111/bjh.17704
Russell CD, Lone NI, Baillie JK. Comorbidities, multimorbidity and COVID-19. Nature Medicine. 2023 Feb 16:1-0.7.
Abdul-Jawad S, Baù L, Alaguthurai T, et al. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021;39(2):257- 275.e256. DOI: https://doi.org/10.1016/j.ccell.2021.01.001
Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K. CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine. 2021 Jul;27(7):1280-9. DOI: https://doi.org/10.1038/s41591-021-01386-7
Bilich T, Roerden M, Maringer Y, Nelde A, Heitmann JS, Dubbelaar ML, Peter A, Hörber S, Bauer J, Rieth J, Wacker M. Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with CancerImmune Responses to SARS-CoV-2 in Patients with Cancer. Cancer Discovery. 2021 Aug 1;11(8):1982-95. DOI: https://doi.org/10.1158/2159-8290.CD-21-0191
Mansi L, Spehner L, Daguindau E, Bouiller K, Almotlak H, Stein U, Bouard A, Kim S, Klajer E, Jary M, Meynard G. Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. European Journal of Cancer. 2021 Jun 1;150:1-9. DOI: https://doi.org/10.1016/j.ejca.2021.03.033
Langerbeins P, Hallek M. COVID-19 in patients with hematologic malignancy. Blood. 2022 May 1 DOI: https://doi.org/10.1182/blood.2021012251
Lee LY, Cazier JB, Starkey T, Briggs SE, Arnold R, Bisht V, Booth S, Campton NA, Cheng VW, Collins G, Curley HM. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. The Lancet Oncology. 2020 Oct 1;21(10):1309-16.
Pagano L, Salmanton-García J, Marchesi F, Busca A, Corradini P, Hoenigl M, Klimko N, Koehler P, Pagliuca A, Passamonti F, Verga L. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). Journal of Hematology & Oncology. 2021 Oct 14;14(1):168.
Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, Angelucci E, Krampera M, Cairoli R, Della Porta MG, Fracchiolla N. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. The Lancet Haematology. 2020 Oct 1;7(10):e737-45. DOI: https://doi.org/10.1016/S2352-3026(20)30251-9
Asch DA, Sheils NE, Islam MN, Chen Y, Werner RM, Buresh J, Doshi JA. Variation in US hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic. JAMA Internal Medicine. 2021 Apr 1;181(4):471-8. DOI: https://doi.org/10.1001/jamainternmed.2020.8193
Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, Hinsley W, Bernal JL, Kall M, Bhatt S, Blomquist P. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort study. The Lancet. 2022 Apr 2;399(10332):1303-12. DOI: https://doi.org/10.1016/S0140-6736(22)00462-7
Niemann CU, da Cunha-Bang C, Helleberg M, Ostrowski SR, Brieghel C. Patients with CLL have a lower risk of death from COVID-19 in the Omicron era. Blood, The Journal of the American Society of Hematology. 2022 Aug 4;140(5):445-50. DOI: https://doi.org/10.1182/blood.2022016147
Pagano L, Salmanton-García J, Marchesi F, Blennow O, da Silva MG, Glenthøj A, van Doesum J, Bilgin YM, Lopez-Garcia A, Federico IT, Rodrigues RN. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from EPICOVIDEHA survey. Blood. 2022 Sep 22.
Heath PT, Galiza EP, Baxter DN, Boffito M, Browne D, Burns F, Chadwick DR, Clark R, Cosgrove C, Galloway J, Goodman AL. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. New England Journal of Medicine. 2021 Sep 23;385(13):1172-83. DOI: https://doi.org/10.1056/NEJMoa2107659
Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal of Medicine. 2021 Feb 4;384(5):403-16. DOI: https://doi.org/10.1056/NEJMoa2035389
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020 Dec 31;383(27):2603-15. DOI: https://doi.org/10.1056/NEJMoa2034577
Zheng C, Shao W, Chen X, Zhang B, Wang G, Zhang W. Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. International Journal of Infectious Diseases. 2022 Jan 1;114:252-60. DOI: https://doi.org/10.1016/j.ijid.2021.11.009
Gong IY, Vijenthira A, Powis M, Calzavara A, Patrikar A, Sutradhar R, Hicks LK, Wilton D, Singh S, Krzyzanowska MK, Cheung MC. Association of COVID-19 vaccination with breakthrough infections and complications in patients with cancer. JAMA Oncology. 2023 Mar 1;9(3):386-94. DOI: https://doi.org/10.1001/jamaoncol.2022.6815
Lee LY, Starkey T, Ionescu MC, Little M, Tilby M, Tripathy AR, Mckenzie HS, Al-Hajji Y, Barnard M, Benny L, Burnett A. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study. The Lancet Oncology. 2022 Jun 1;23(6):748-57. DOI: https://doi.org/10.1016/S1470-2045(22)00202-9
Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Levin EG, Rubin C, Indenbaum V, Tal I. Covid-19 breakthrough infections in vaccinated health care workers. New England Journal of Medicine. 2021 Oct 14;385(16):1474-84. DOI: https://doi.org/10.1056/NEJMoa2109072
Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N. Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell. 2021 Aug 9;39(8):1081-90. DOI: https://doi.org/10.1016/j.ccell.2021.06.002
Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. Cancer Cell. 2021 Oct 11;39(10):1297-9. DOI: https://doi.org/10.1016/j.ccell.2021.09.001
Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies. Cancer Cell. 2021 Aug 9;39(8):1031-3. DOI: https://doi.org/10.1016/j.ccell.2021.07.012
Lim SH, Campbell N, Johnson M, Joseph-Pietras D, Collins GP, O’Callaghan A, Fox CP, Ahearne M, Johnson PW, Goldblatt D, Davies AJ. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. The Lancet Haematology. 2021 Aug 1;8(8):e542-4. DOI: https://doi.org/10.1016/S2352-3026(21)00199-X
Levin EG, Lustig Y, Cohen C, Fluss R, Indenbaum V, Amit S, Doolman R, Asraf K, Mendelson E, Ziv A, Rubin C. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. New England Journal of Medicine. 2021 Dec 9;385(24):e84. DOI: https://doi.org/10.1056/NEJMoa2114583
Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA. Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. Cancer Cell. 2022 Jan 10;40(1):3-5. DOI: https://doi.org/10.1016/j.ccell.2021.11.006
Kohn M, Delord M, Chbat M, Guemriche A, Merabet F, Roupie AL, Lombion N, Farhat H, Longval T, Cabannes-Hamy A, Lambert J. A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia. Haematologica. 2022 Jun 6;107(6):1454. DOI: https://doi.org/10.3324/haematol.2021.280026
Shen Y, Freeman JA, Holland J, Naidu K, Solterbeck A, Van Bilsen N, Downe P, Kerridge I, Wallman L, Akerman A, Aggarwal A. Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion. Blood, The Journal of the American Society of Hematology. 2022 Dec 22;140(25):2709-21. DOI: https://doi.org/10.1182/blood.2022017814
Haggenburg S, Hofsink Q, Lissenberg-Witte BI, Broers AE, Van Doesum JA, Van Binnendijk RS, Den Hartog G, Bhoekhan MS, Haverkate NJ, Burger JA, Bouhuijs JH. Antibody response in immunocompromised patients with hematologic cancers who received a 3-dose mRNA-1273 vaccination schedule for COVID-19. JAMA oncology. 2022 Oct 1;8(10):1477-83.
Jiménez M, Roldán E, Fernández-Naval C, Villacampa G, Martinez-Gallo M, Medina-Gil D, Peralta- Garzón S, Pujadas G, Hernández C, Pagès C, Gironella M. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. Blood Advances. 2022 Feb 8;6(3):774-84. DOI: https://doi.org/10.1182/bloodadvances.2021006101
Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, Reis BY, Balicer RD. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. The Lancet. 2021 Dec 4;398(10316):2093-100. DOI: https://doi.org/10.1016/S0140-6736(21)02249-2
Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, Yuan Y, Seegobin S, Ellery A, Levinson DJ, Ambery P. Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of COVID-19. New England Journal of Medicine. 2022 Jun 9;386(23):2188-200. DOI: https://doi.org/10.1056/NEJMoa2116620
Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, COVID-19 Genomics UK (COG-UK) Consortium, Willett BJ, Thomson E, Gupta RK, Peacock SJ, Robertson DL. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nature Reviews Microbiology. 2023 Feb;21(2):112-24. DOI: https://doi.org/10.1038/s41579-022-00809-7
Dacon C, Tucker C, Peng L, Lee CC, Lin TH, Yuan M, Cong Y, Wang L, Purser L, Williams JK, Pyo CW. Broadly neutralizing antibodies target the coronavirus fusion peptide. Science. 2022 Aug 12;377(6607):728-35. DOI: https://doi.org/10.1126/science.abq3773
Living Systematic Review. Vol. 2023: Infectious Diseases Data Observatory.
WHO. Therapeutics and COVID-19: living guideline. Vol. 2023.
Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, Oguchi G, Ryan P, Nielsen BU, Brown M, Hidalgo A. Early remdesivir to prevent progression to severe Covid-19 in outpatients. New England Journal of Medicine. 2022 Jan 27;386(4):305-15. DOI: https://doi.org/10.1056/NEJMoa2116846
Levy I, Lavi A, Zimran E, Grisariu S, Aumann S, Itchaki G, Berger T, Raanani P, Harel R, Aviv A, Lavi N. COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome. Leukemia & Lymphoma. 2021 Dec 6;62(14):3384-93. DOI: https://doi.org/10.1080/10428194.2021.1966782
Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, Baniecki M, Hendrick VM, Damle B, Simón-Campos A, Pypstra R. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. New England Journal of Medicine. 2022 Apr 14;386(15):1397-408. DOI: https://doi.org/10.1056/NEJMoa2118542
COVID-19 drug interactions. Vol. 2023: Liverpool COVID-19 Interactions Checker. https://www. covid19-druginteractions.org/. Accessed April 4, 2023.
Nirmatrelvir/Ritonavir (Paxlovid) Management of Drug-Drug Interactions in Oncology. Vol. 2023: University Health Network. https://www.antimicrobialstewardship.com/paxlovid-ddi-oncology. Accessed April 4, 2023.
Iketani S, Liu L, Guo Y, Liu L, Chan JF, Huang Y, Wang M, Luo Y, Yu J, Chu H, Chik KK. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022 Apr 21;604(7906):553-6. DOI: https://doi.org/10.1038/s41586-022-04594-4
Li P, Wang Y, Lavrijsen M, Lamers MM, de Vries AC, Rottier RJ, Bruno MJ, Peppelenbosch MP, Haagmans BL, Pan Q. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Research. 2022 Mar;32(3):322-4. DOI: https://doi.org/10.1038/s41422-022-00618-w
Takashita E, Kinoshita N, Yamayoshi S, Sakai-Tagawa Y, Fujisaki S, Ito M, Iwatsuki-Horimoto K, Chiba S, Halfmann P, Nagai H, Saito M. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. New England Journal of Medicine. 2022 Mar 10;386(10):995-8. DOI: https://doi.org/10.1056/NEJMc2119407
Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P, Gao Y, Cui Z, Zhang Q, Meng X, Gui H. VV116 versus nirmatrelvir–ritonavir for oral treatment of covid-19. New England Journal of Medicine. 2023 Feb 2;388(5):406-17. DOI: https://doi.org/10.1056/NEJMoa2208822
Reis G, Moreira Silva EA, Medeiros Silva DC, Thabane L, Campos VH, Ferreira TS, Santos CV, Nogueira AM, Almeida AP, Savassi LC, Figueiredo-Neto AD. Early treatment with pegylated interferon lambda for covid-19. New England Journal of Medicine. 2023 Feb 9;388(6):518-28. DOI: https://doi.org/10.1056/NEJMoa2209760
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D. Remdesivir for the treatment of Covid-19. New England Journal of Medicine. 2020 Nov 5;383(19):1813-26. DOI: https://doi.org/10.1056/NEJMoa2007764
Amstutz A, Speich B, Mentré F, Rueegg CS, Belhadi D, Assoumou L, Burdet C, Murthy S, Dodd LE, Wang Y, Tikkinen KA. Effects of remdesivir in patients hospitalised with COVID-19: a systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Respiratory Medicine. 2023 Feb 21. DOI: https://doi.org/10.1016/S2213-2600(22)00528-8
RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. New England Journal of Medicine. 2021 Feb 25;384(8):693-704. DOI: https://doi.org/10.1056/NEJMoa2021436
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz- Palacios GM, Hsieh L, Kline S, Tapson V. Baricitinib plus remdesivir for hospitalized adults with Covid-19. New England Journal of Medicine. 2021 Mar 4;384(9):795-807. DOI: https://doi.org/10.1056/NEJMoa2031994
ASH Guidelines on Use of Anticoagulation in Patients with COVID-19. Vol. 2023: American Society of Hematology.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Canadian Hematology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
